Suppr超能文献

术前干预和肿瘤大小影响视神经鞘脑膜瘤(ONSM)精准放疗后的临床结果。

Prior surgical intervention and tumor size impact clinical outcome after precision radiotherapy for the treatment of optic nerve sheath meningiomas (ONSM).

机构信息

Department of Radiation Oncology, University Hospital of Heidelberg, Im Neuenheimer Feld 400, Heidelberg, Germany.

出版信息

Radiat Oncol. 2011 Sep 18;6:117. doi: 10.1186/1748-717X-6-117.

Abstract

PURPOSE

We analyzed our long-term experience with fractionated stereotactic radiotherapy (FSRT) in patients with meningioma of the optic nerve sheath (ONSM).

PATIENTS AND METHODS

Between January 1991 and January 2010, 40 patients with ONSM were treated using FSRT. Of these, 19 patients received radiotherapy as primary treatment, and 21 patients were treated after surgical resection. The median target volume was 9.2 ml, median total dose was 54 Gy in median single fractions of 1,8 Gy.

RESULTS

Local progression-free survival was 100%. Median survival after FSRT was 60 months (range 4-228 months). In all patients overall toleration of FSRT was very good. Acute toxicity was mild. Prior to RT, 29 patients complained about any kind of visual impairment including visual field deficits, diplopia or amaurosis. Prior surgical resection was identified as a negative prognostic factor for visual outcome, whereas patients with larger tumor volumes demonstrated a higher number of patients with improvement of pre-existing visual deficits.

CONCLUSION

Long-term outcome after FSRT for ONSM shows improved vision in patients not treated surgically prior to RT; moreover, the best improvement of visual deficits are observed in patients with larger target volumes. The absence of tumor recurrences supports that FSRT is a strong alternative to surgical resection especially in small tumors without extensive compression of normal tissue structures.

摘要

目的

我们分析了我们在视神经鞘膜脑膜瘤(ONSM)患者中使用分次立体定向放射治疗(FSRT)的长期经验。

患者和方法

1991 年 1 月至 2010 年 1 月期间,40 例 ONSM 患者接受 FSRT 治疗。其中,19 例患者接受放疗作为初始治疗,21 例患者在手术切除后接受治疗。中位靶体积为 9.2ml,中位总剂量为 54Gy,中位单次剂量为 1.8Gy。

结果

局部无进展生存率为 100%。FSRT 后的中位生存期为 60 个月(范围 4-228 个月)。所有患者对 FSRT 的总体耐受性均非常好。急性毒性轻微。在 RT 之前,29 名患者抱怨任何类型的视力障碍,包括视野缺损、复视或失明。先前的手术切除被确定为视觉结果的负预后因素,而肿瘤体积较大的患者表现出更多的患者存在先前存在的视觉缺陷改善。

结论

FSRT 治疗 ONSM 的长期结果显示,未经手术治疗的患者视力得到改善;此外,在靶体积较大的患者中观察到视觉缺陷的最佳改善。没有肿瘤复发支持 FSRT 是手术切除的强有力替代方法,特别是在没有广泛压迫正常组织结构的小肿瘤中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e831/3192676/bccdc36213c6/1748-717X-6-117-3.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验